Nektar Therapeutics (NASDAQ:NKTR) has reached overbought status with an RSI(14) at 92.26 .

The Relative Strength Index (RSI) is a recognized technical indicator used to determine strengthening and weakening momentum in price action. An RSI above 70 is considered overbought and under 30 is considered oversold. Overbought is a technical condition that occurs when prices are considered too high and may be susceptible to a decline.

Volatility

Nektar Therapeutics’s stock has a beta of 1.19 meaning it is more volatile than the market overall which by definition has a beta of 1. Stocks with a beta lower than the market are less risky and those with a higher beta are more risky than the market over the long haul.

The stock’s Average True Range (ATR) is sitting at 2.51. The ATR is an indicator of volatility. A high or low ATR doesn’t tell you which way a stock will move but is a signal that it is likely to move.

Short Interest

Short traders are feeling a little more bullish on shares of Nektar Therapeutics lately if you pay attention to the motion in short interest. The company had a fall in short interest of -1.29% between September 29, 2017 and October 13, 2017. Short shares fell 163,835 over that timeframe. Days to cover increased 2.0 to 12.0 and the short interest percentage is 0.08% as of October 13.

Insider Activity

Here is a rundown on some insider market activity for Nektar Therapeutics (NASDAQ:NKTR). Sr VP Stephen K. Doberstein disclosed the sale of 396,323 shares of (NKTR). The shares were sold on November 8th for a price of $26.95. The Sr VP now owns $838,199 of the stock per the Form 4 SEC filing. Sr VP Maninder Hora sold 5,117 shares at an average price of $25.07 on Mon the 6th. That brings the Sr VP’s holdings to $1,459,901 per an SEC filing yesterday.

President & CEO Howard W. Robin let go of 83,334 shares at an average price of $23.57 on Wed the 1st. Robin now owns $3,594,519 of stock as reported to the SEC.

Recent Analyst Ratings

Canaccord Genuity updated guidance on NKTR with a rating of “Buy”. On November 8 Jefferies Group LLC kept the stock rating at “Buy” targeting a price of $35.00.

November 8 investment analysts at Mizuho held the stock rating at “Buy” projecting a price of $30.00. On November 7 analysts at Cowen and Company updated coverage of NKTR by announcing an initial rating of “Outperform”.

On September 26, 2017 Mizuho updated its forecast on NKTR giving it an initial rating of “Buy”. On August 18 Jefferies Group LLC maintained a stock rating of “Buy” with a current price target of $23.00.

The P/E ratio is currently N/A and market cap is 7.79B. In the last earnings report the EPS was $-0.71 with 157.47M shares currently outstanding.

Company Information

Nektar Therapeutics, launched on June 3, 1998, is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Business’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD..